Edwards Lifesciences CEO sells 23,100 shares

Q: How many EW shares did CEO Bernard J. Zovighian sell?

On November 9, 2026, he sold 9,184 shares at a weighted average of $103.3851 per share and 13,916 shares at a weighted average of $102.7803 per share. The sales were made under a Rule 10b5-1 trading plan adopted July 28, 2026.

Q: How many options did EW CEO Bernard J. Zovighian exercise?

On November 9, 2026, Zovighian exercised options for 23,100 shares at a $72.68 exercise price and acquired 23,100 common shares. The options were granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020.

On November 9, 2026, Zovighian's reported indirect holdings included 3,734 shares through a 401(k) and 8,916 shares held by trust.

Available on EDGAR 11/09/2026 - 04:29 PM EST Accepted by SEC EDGAR 11/09/2026 - 04:29 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Edwards Lifesciences Corp CEO and director Bernard J. Zovighian exercised options for 23,100 shares at a $72.68 exercise price on November 9, 2026, acquiring 23,100 common shares. He also reported two sales that day: 9,184 shares at a weighted average of $103.3851 per share and 13,916 shares at a weighted average of $102.7803 per share. The transactions were made under a Rule 10b5-1 trading plan adopted July 28, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 23,100 shares ($701K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Zovighian Bernard J

Role CEO

Sold 23,100 shs ($2.38M)

Approx. gross sale proceeds $2.38M

Approx. exercise cost $1.68M

Approx. pre-tax spread $701K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Acquire) ^F4	23,100	$0.00	$0.00
Exercise	Common Stock ^F1	23,100	$72.68	$1.68M
Sale	Common Stock ^{F1, F2}	9,184	$103.3851	$949K
Sale	Common Stock ^{F1, F3}	13,916	$102.7803	$1.43M
Holding	Common Stock	--	--	--
Holding	Common Stock	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Acquire) — 23,100 options (Direct); Common Stock — 98,845 shares (Direct); Common Stock — 3,733.5603 shares (Indirect, 401(k)); Common Stock — 8,915.6499 shares (Indirect, By Trust)

Footnotes (4)

F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 28, 2026.
F2. This transaction was executed in multiple trades at prices ranging from $103.18 to $103.66 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3. This transaction was executed in multiple trades at prices ranging from $102.17 to $103.16 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F4. These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

Key Figures

Options exercised: 23,100 shares Exercise price: $72.68 per share Common shares acquired: 23,100 shares +4 more

7 metrics

Options exercised 23,100 shares November 9, 2026

Exercise price $72.68 per share Options exercised on November 9, 2026

Common shares acquired 23,100 shares November 9, 2026

Shares sold 9,184 shares November 9, 2026

Weighted average sale price $103.3851 per share 9,184-share sale on November 9, 2026

Shares sold 13,916 shares November 9, 2026

Weighted average sale price $102.7803 per share 13,916-share sale on November 9, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Employee Stock Option (Right to Acquire), vested and exercisable

4 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"reflects the weighted average sale price"

Employee Stock Option (Right to Acquire) technical

"Employee Stock Option (Right to Acquire)"

vested and exercisable technical

"scheduled to become vested and exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many EW shares did CEO Bernard J. Zovighian sell?

On November 9, 2026, he sold 9,184 shares at a weighted average of $103.3851 per share and 13,916 shares at a weighted average of $102.7803 per share. The sales were made under a Rule 10b5-1 trading plan adopted July 28, 2026.

How many options did EW CEO Bernard J. Zovighian exercise?

On November 9, 2026, Zovighian exercised options for 23,100 shares at a $72.68 exercise price and acquired 23,100 common shares. The options were granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zovighian Bernard J

(Last)

(First)

(Middle)

ONE EDWARDS WAY

(Street)

IRVINE

CALIFORNIA

92614

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/09/2026		M⁽¹⁾		23,100	A	$72.68	121,945	D
Common Stock	11/09/2026		S⁽¹⁾		9,184	D	$103.3851⁽²⁾	112,761	D
Common Stock	11/09/2026		S⁽¹⁾		13,916	D	$102.7803⁽³⁾	98,845	D
Common Stock								3,733.5603	I	401(k)
Common Stock								8,915.6499	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (Right to Acquire)	$72.68	11/09/2026		M			23,100	⁽⁴⁾	05/06/2027	Common Stock	23,100	$0.0000	23,100	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 28, 2026.

2. This transaction was executed in multiple trades at prices ranging from $103.18 to $103.66 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $102.17 to $103.16 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

4. These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	11/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR